Free Trial

STAAR Surgical Q4 2023 Earnings Report

STAAR Surgical logo
$24.26 -1.18 (-4.64%)
(As of 12/18/2024 05:33 PM ET)

STAAR Surgical Earnings Headlines

Analysts Set STAAR Surgical (NASDAQ:STAA) PT at $42.83
Trump’s Sending THIS Crypto Higher on Purpose
Discover the coin set to explode before 2025! Trump could trigger THIS crypto coin…
Staar Surgical price target lowered to $28 from $31 at Canaccord
Staar Surgical price target lowered to $23 from $27 at Morgan Stanley
Staar Surgical Co (STAA) Shares Down 3.45% on Dec 2
See More STAAR Surgical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like STAAR Surgical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on STAAR Surgical and other key companies, straight to your email.

About STAAR Surgical

STAAR Surgical (NASDAQ:STAA) Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.

View STAAR Surgical Profile

More Earnings Resources from MarketBeat

Upcoming Earnings